Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983005576> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2983005576 endingPage "vi85" @default.
- W2983005576 startingPage "vi85" @default.
- W2983005576 abstract "Abstract Taniraleucel (CYNK-001) is an allogeneic, off-the-shelf cell therapy enriched for CD56+/CD3- NK cells expanded from placental CD34+ cells. CYNK-001 exhibits in vitro cytotoxicity against various cancer cell types, including glioblastoma multiforme (GBM), and secretes cytokines during co-culture with cancer cells. To evaluate in vivo anti-GBM activity, safety and persistence of CYNK-001, we conducted two studies in the non-obese diabetic (NOD)-scid IL2Rgammanull (NSG) immune deficient mouse models. First, CYNK-001 in vivo anti-GBM activity was assessed in a U-87MG orthotopic NSG mouse model. Luciferase-expressing U-87MG cells were stereotactically injected into the cranium of NSG mice at Day 0. Repeated dosing of 0.5x106 CYNK-001 cells at Day 14 and Day 25 by intracranial (IC) injection showed a statistically significant reduction of Bioluminescence Imaging (BLI) compared to the PBS control. Furthermore, intravenous (IV) and intracerebroventricular (ICV) routes of administration were evaluated compared to IC. CYNK-001 administered with IC resulted in a greater reduction of BLI than IV and ICV. Second, a single-dose toxicity study was conducted in naïve NSG mice to assess the safety and persistence of CYNK-001 following an IC injection. IC administration of 1×106 CYNK-001 was well tolerated, and no adverse clinical symptoms were observed. Quantitative polymerase chain reaction (qPCR) analysis for the human telomerase reverse transcriptase (hTERT) gene revealed that CYNK-001 persisted in the brain up to seven days. Our studies demonstrated that CYNK-001with IC administration appears safe and well tolerated in naïve as well as U-87MG tumor bearing NSG mice. Furthermore, CYNK-001 anti-tumor activity was exhibited in a GBM orthotopic NSG mouse model. Taken together, our data support a safety and efficacy evaluation of CYNK-001 in patients with GBM. A Phase 1 study in adult patients with recurrent/refractory GBM is planned to start this year evaluating the safety and efficacy of CYNK-001 with both IV and IC administrations." @default.
- W2983005576 created "2019-11-22" @default.
- W2983005576 creator A5003517607 @default.
- W2983005576 creator A5016592850 @default.
- W2983005576 creator A5049730819 @default.
- W2983005576 creator A5082547105 @default.
- W2983005576 creator A5087308159 @default.
- W2983005576 date "2019-11-01" @default.
- W2983005576 modified "2023-10-16" @default.
- W2983005576 title "EXTH-16. HUMAN PLACENTAL HEMATOPOIETIC STEM CELL DERIVED NATURAL KILLER CELLS FOR GLIOBLASTOMA IMMUNOTHERAPY" @default.
- W2983005576 doi "https://doi.org/10.1093/neuonc/noz175.350" @default.
- W2983005576 hasPublicationYear "2019" @default.
- W2983005576 type Work @default.
- W2983005576 sameAs 2983005576 @default.
- W2983005576 citedByCount "0" @default.
- W2983005576 crossrefType "journal-article" @default.
- W2983005576 hasAuthorship W2983005576A5003517607 @default.
- W2983005576 hasAuthorship W2983005576A5016592850 @default.
- W2983005576 hasAuthorship W2983005576A5049730819 @default.
- W2983005576 hasAuthorship W2983005576A5082547105 @default.
- W2983005576 hasAuthorship W2983005576A5087308159 @default.
- W2983005576 hasBestOaLocation W29830055761 @default.
- W2983005576 hasConcept C10205521 @default.
- W2983005576 hasConcept C104317684 @default.
- W2983005576 hasConcept C109159458 @default.
- W2983005576 hasConcept C111335760 @default.
- W2983005576 hasConcept C125593758 @default.
- W2983005576 hasConcept C150903083 @default.
- W2983005576 hasConcept C161997846 @default.
- W2983005576 hasConcept C203014093 @default.
- W2983005576 hasConcept C207001950 @default.
- W2983005576 hasConcept C2777701055 @default.
- W2983005576 hasConcept C28328180 @default.
- W2983005576 hasConcept C502942594 @default.
- W2983005576 hasConcept C54009773 @default.
- W2983005576 hasConcept C54355233 @default.
- W2983005576 hasConcept C55493867 @default.
- W2983005576 hasConcept C55851684 @default.
- W2983005576 hasConcept C71924100 @default.
- W2983005576 hasConcept C81885089 @default.
- W2983005576 hasConcept C86803240 @default.
- W2983005576 hasConcept C8891405 @default.
- W2983005576 hasConcept C94581717 @default.
- W2983005576 hasConcept C98274493 @default.
- W2983005576 hasConceptScore W2983005576C10205521 @default.
- W2983005576 hasConceptScore W2983005576C104317684 @default.
- W2983005576 hasConceptScore W2983005576C109159458 @default.
- W2983005576 hasConceptScore W2983005576C111335760 @default.
- W2983005576 hasConceptScore W2983005576C125593758 @default.
- W2983005576 hasConceptScore W2983005576C150903083 @default.
- W2983005576 hasConceptScore W2983005576C161997846 @default.
- W2983005576 hasConceptScore W2983005576C203014093 @default.
- W2983005576 hasConceptScore W2983005576C207001950 @default.
- W2983005576 hasConceptScore W2983005576C2777701055 @default.
- W2983005576 hasConceptScore W2983005576C28328180 @default.
- W2983005576 hasConceptScore W2983005576C502942594 @default.
- W2983005576 hasConceptScore W2983005576C54009773 @default.
- W2983005576 hasConceptScore W2983005576C54355233 @default.
- W2983005576 hasConceptScore W2983005576C55493867 @default.
- W2983005576 hasConceptScore W2983005576C55851684 @default.
- W2983005576 hasConceptScore W2983005576C71924100 @default.
- W2983005576 hasConceptScore W2983005576C81885089 @default.
- W2983005576 hasConceptScore W2983005576C86803240 @default.
- W2983005576 hasConceptScore W2983005576C8891405 @default.
- W2983005576 hasConceptScore W2983005576C94581717 @default.
- W2983005576 hasConceptScore W2983005576C98274493 @default.
- W2983005576 hasIssue "Supplement_6" @default.
- W2983005576 hasLocation W29830055761 @default.
- W2983005576 hasLocation W29830055762 @default.
- W2983005576 hasOpenAccess W2983005576 @default.
- W2983005576 hasPrimaryLocation W29830055761 @default.
- W2983005576 hasRelatedWork W2035370065 @default.
- W2983005576 hasRelatedWork W2055670125 @default.
- W2983005576 hasRelatedWork W2084319477 @default.
- W2983005576 hasRelatedWork W2119511363 @default.
- W2983005576 hasRelatedWork W2125308050 @default.
- W2983005576 hasRelatedWork W2148642895 @default.
- W2983005576 hasRelatedWork W2411769506 @default.
- W2983005576 hasRelatedWork W3025676706 @default.
- W2983005576 hasRelatedWork W4239901736 @default.
- W2983005576 hasRelatedWork W979357040 @default.
- W2983005576 hasVolume "21" @default.
- W2983005576 isParatext "false" @default.
- W2983005576 isRetracted "false" @default.
- W2983005576 magId "2983005576" @default.
- W2983005576 workType "article" @default.